Aviance Capital Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.3M | Sell |
6,879
-452
| -6% | -$79K | 0.15% | 124 |
|
|
2025
Q4 | $1.25M | Sell |
7,331
-338
| -4% | -$51.8K | 0.14% | 133 |
|
|
2025
Q3 | $1.01M | Sell |
7,669
-148
| -2% | -$17.8K | 0.12% | 157 |
|
|
2025
Q2 | $830K | Sell |
7,817
-1,000
| -11% | -$109K | 0.11% | 167 |
|
|
2025
Q1 | $1.09M | Sell |
8,817
-94
| -1% | -$12.3K | 0.15% | 137 |
|
|
2024
Q4 | $1.1M | Sell |
8,911
-841
| -9% | -$99.1K | 0.15% | 134 |
|
|
2024
Q3 | $1.09M | Buy |
9,752
+3
| +0% | +$329 | 0.14% | 154 |
|
|
2024
Q2 | $1.04M | Buy |
9,749
+41
| +0.4% | +$4.51K | 0.15% | 138 |
|
|
2024
Q1 | $1.17M | Sell |
9,708
-795
| -8% | -$97.4K | 0.17% | 130 |
|
|
2023
Q4 | $1.29M | Sell |
10,503
-80
| -0.8% | -$9.98K | 0.28% | 93 |
|
|
2023
Q3 | $1.37M | Buy |
10,583
+287
| +3% | +$38.2K | 0.31% | 86 |
|
|
2023
Q2 | $1.28M | Buy |
10,296
+80
| +0.8% | +$10.8K | 0.27% | 106 |
|
|
2023
Q1 | $1.49M | Buy |
10,216
+99
| +1% | +$14.6K | 0.33% | 82 |
|
|
2022
Q4 | $1.61M | Sell |
10,117
-447
| -4% | -$65.5K | 0.38% | 67 |
|
|
2022
Q3 | $1.41M | Sell |
10,564
-34
| -0.3% | -$5.17K | 0.35% | 84 |
|
|
2022
Q2 | $1.65M | Sell |
10,598
-280
| -3% | -$43.1K | 0.37% | 75 |
|
|
2022
Q1 | $1.69M | Sell |
10,878
-468
| -4% | -$67.9K | 0.31% | 94 |
|
|
2021
Q4 | $1.45M | Hold |
11,346
| – | – | 0.24% | 103 |
|
|
2021
Q3 | $1.48M | Buy |
11,346
+403
| +4% | +$60.9K | 0.26% | 105 |
|
|
2021
Q2 | $1.94M | Sell |
10,943
-21
| -0.2% | -$3.64K | 0.34% | 70 |
|
|
2021
Q1 | $1.8M | Sell |
10,964
-517
| -5% | -$85.1K | 0.35% | 69 |
|
|
2020
Q4 | $1.9M | Sell |
11,481
-40
| -0.3% | -$5.96K | 0.38% | 62 |
|
|
2020
Q3 | $1.64M | Hold |
11,521
| – | – | 0.37% | 69 |
|
|
2020
Q2 | $1.27M | Sell |
11,521
-165
| -1% | -$18.2K | 0.31% | 78 |
|
|
2020
Q1 | $1.17M | Sell |
11,686
-1,066
| -8% | -$138K | 0.37% | 68 |
|
|
2019
Q4 | $1.9M | Sell |
12,752
-1,544
| -11% | -$210K | 0.49% | 57 |
|
|
2019
Q3 | $1.83M | Sell |
14,296
-724
| -5% | -$97K | 0.54% | 49 |
|
|
2019
Q2 | $2.14M | Buy |
15,020
+655
| +5% | +$88K | 0.59% | 37 |
|
|
2019
Q1 | $2.05M | Buy |
14,365
+587
| +4% | +$76.6K | 0.59% | 37 |
|
|
2018
Q4 | $1.71M | Sell |
13,778
-850
| -6% | -$126K | 0.6% | 39 |
|
|
2018
Q3 | $2.46M | Sell |
14,628
-270
| -2% | -$46.4K | 0.59% | 33 |
|
|
2018
Q2 | $2.57M | Sell |
14,898
-765
| -5% | -$125K | 0.74% | 26 |
|
|
2018
Q1 | $2.36M | Sell |
15,663
-435
| -3% | -$63.8K | 0.71% | 29 |
|
|
2017
Q4 | $2.17M | Sell |
16,098
-425
| -3% | -$58.9K | 0.72% | 29 |
|
|
2017
Q3 | $2.42M | Sell |
16,523
-1,830
| -10% | -$277K | 0.82% | 23 |
|
|
2017
Q2 | $2.85M | Buy |
18,353
+185
| +1% | +$28.3K | 0.92% | 20 |
|
|
2017
Q1 | $2.64M | Sell |
18,168
-55
| -0.3% | -$7.16K | 0.96% | 21 |
|
|
2016
Q4 | $1.99M | Sell |
18,223
-4,065
| -18% | -$453K | 0.7% | 34 |
|
|
2016
Q3 | $2.71M | Sell |
22,288
-2,465
| -10% | -$332K | 0.96% | 24 |
|
|
2016
Q2 | $3.5M | Buy |
24,753
+3,065
| +14% | +$452K | 1.29% | 10 |
|
|
2016
Q1 | $2.83M | Buy |
21,688
+318
| +1% | +$39.6K | 0.98% | 19 |
|
|
2015
Q4 | $3M | Sell |
21,370
-1,995
| -9% | -$276K | 1.03% | 18 |
|
|
2015
Q3 | $3.1M | Buy |
23,365
+365
| +2% | +$62.8K | 1.27% | 11 |
|
|
2015
Q2 | $4.05M | Buy |
23,000
+175
| +0.8% | +$31.4K | 1.51% | 8 |
|
|
2015
Q1 | $3.94M | Sell |
22,825
-325
| -1% | -$55.8K | 1.45% | 7 |
|
|
2014
Q4 | $3.79M | Sell |
23,150
-1,195
| -5% | -$198K | 1.42% | 7 |
|
|
2014
Q3 | $3.91M | Sell |
24,345
-500
| -2% | -$76.9K | 1.48% | 6 |
|
|
2014
Q2 | $3.65M | Buy |
24,845
+895
| +4% | +$124K | 1.43% | 6 |
|
|
2014
Q1 | $3.32M | Sell |
23,950
-2,725
| -10% | -$410K | 1.4% | 8 |
|
|
2013
Q4 | $3.38M | Buy |
26,675
+125
| +0.5% | +$12.9K | 1.42% | 13 |
|
|
2013
Q3 | $2.44M | Sell |
26,550
-800
| -3% | -$64.5K | 1.14% | 19 |
|
|
2013
Q2 | $1.88M | Buy |
+27,350
| New | +$1.67M | 1.02% | 25 |
|
Other funds holding JAZZ
VPM
VCM
EC
Aviance Capital Partners's JAZZ Position: Q1 2026 in Review
Aviance Capital Partners reduced its Jazz Pharmaceuticals (JAZZ) stake by 6.2% in Q1 2026, selling an estimated $79K and leaving 6,879 shares worth $1.3M. The position accounts for 0.15% of the portfolio, ranked #124.
Aviance Capital Partners first reported a position in JAZZ in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.05M in Q2 2015. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Aviance Capital Partners held 6,879 shares of Jazz Pharmaceuticals worth $1.3M as of Q1 2026.
- Aviance Capital Partners sold 452 Jazz Pharmaceuticals shares in Q1 2026, an estimated $79K.
- Jazz Pharmaceuticals made up 0.15% of Aviance Capital Partners's portfolio in Q1 2026, its #124 holding.
- Aviance Capital Partners first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Aviance Capital Partners's Jazz Pharmaceuticals position peaked at $4.05M in Q2 2015.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Aviance Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.